These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26034208)

  • 21. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
    Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
    J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
    Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
    Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.
    Ferraris P; Chandra PK; Panigrahi R; Aboulnasr F; Chava S; Kurt R; Pawlotsky JM; Wilkens L; Osterlund P; Hartmann R; Balart LA; Wu T; Dash S
    Am J Pathol; 2016 Apr; 186(4):938-51. PubMed ID: 26896692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.
    Golden-Mason L; Bambha KM; Cheng L; Howell CD; Taylor MW; Clark PJ; Afdhal N; Rosen HR;
    Hepatology; 2011 Nov; 54(5):1559-69. PubMed ID: 21983945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.
    Olmedo DB; Cader SA; Porto LC
    J Med Virol; 2015 Oct; 87(10):1702-15. PubMed ID: 25970604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells.
    Miot C; Beaumont E; Duluc D; Le Guillou-Guillemette H; Preisser L; Garo E; Blanchard S; Hubert Fouchard I; Créminon C; Lamourette P; Fremaux I; Calès P; Lunel-Fabiani F; Boursier J; Braum O; Fickenscher H; Roingeard P; Delneste Y; Jeannin P
    Gut; 2015 Sep; 64(9):1466-75. PubMed ID: 25183206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of
    Nakamoto S; Imazeki F; Kanda T; Wu S; Nakamura M; Yasui S; Tawada A; Mikata R; Chiba T; Arai M; Yokosuka O; Shirasawa H
    Int J Med Sci; 2017; 14(11):1088-1093. PubMed ID: 29104462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
    O'Connor KS; Parnell G; Patrick E; Ahlenstiel G; Suppiah V; van der Poorten D; Read SA; Leung R; Douglas MW; Yang JY; Stewart GJ; Liddle C; George J; Booth DR
    Genes Immun; 2014 Mar; 15(2):88-94. PubMed ID: 24335707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.
    Ahlenstiel G; Titerence RH; Koh C; Edlich B; Feld JJ; Rotman Y; Ghany MG; Hoofnagle JH; Liang TJ; Heller T; Rehermann B
    Gastroenterology; 2010 Jan; 138(1):325-35.e1-2. PubMed ID: 19747917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection.
    Nguyen LT; Van Nguyen D; Carr MJ; Hall WW; Nguyen LA
    Arch Virol; 2018 Jan; 163(1):115-124. PubMed ID: 29022122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection.
    Sultanik PS; Casrouge A; Alanio C; Mottez E; Rosa-Hézode I; Hézode C; Renard P; Bousquet L; Pellet P; Uzé G; Pol S; Albert ML; Mallet V
    J Viral Hepat; 2015 Jun; 22(6):524-34. PubMed ID: 25382001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.
    Pembroke T; Christian A; Jones E; Hills RK; Wang EC; Gallimore AM; Godkin A
    Gut; 2014 Mar; 63(3):515-24. PubMed ID: 23665989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection.
    Azam S; Manzoor S; Imran M; Ashraf J; Ashraf S; Resham S; Ghani E
    Viral Immunol; 2015 May; 28(4):222-8. PubMed ID: 25798684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery.
    Honegger JR; Tedesco D; Kohout JA; Prasad MR; Price AA; Lindquist T; Ohmer S; Moore-Clingenpeel M; Grakoui A; Walker CM
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10684-9. PubMed ID: 27601657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.